NASDAQ:ARQT Arcutis Biotherapeutics (ARQT) Stock Price, News & Analysis $9.60 +0.30 (+3.23%) (As of 07/3/2024 ET) Add Compare Share Share Today's Range$9.31▼$9.9050-Day Range$7.24▼$9.9252-Week Range$1.76▼$13.17Volume1.55 million shsAverage Volume2.74 million shsMarket Capitalization$1.11 billionP/E RatioN/ADividend YieldN/APrice Target$25.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Arcutis Biotherapeutics alerts: Email Address Arcutis Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside164.3% Upside$25.38 Price TargetShort InterestBearish22.48% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.71Based on 10 Articles This WeekInsider TradingSelling Shares$378,950 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.60) to ($1.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.60 out of 5 starsMedical Sector701st out of 896 stocksPharmaceutical Preparations Industry327th out of 424 stocks 3.4 Analyst's Opinion Consensus RatingArcutis Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageArcutis Biotherapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Arcutis Biotherapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted22.48% of the outstanding shares of Arcutis Biotherapeutics have been sold short.Short Interest Ratio / Days to CoverArcutis Biotherapeutics has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Arcutis Biotherapeutics has recently increased by 5.60%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcutis Biotherapeutics does not currently pay a dividend.Dividend GrowthArcutis Biotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARQT. Previous Next 3.7 News and Social Media Coverage News SentimentArcutis Biotherapeutics has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Arcutis Biotherapeutics this week, compared to 5 articles on an average week.Search Interest13 people have searched for ARQT on MarketBeat in the last 30 days. This is an increase of 8% compared to the previous 30 days.MarketBeat Follows7 people have added Arcutis Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcutis Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $378,950.00 in company stock.Percentage Held by InsidersOnly 9.50% of the stock of Arcutis Biotherapeutics is held by insiders.Read more about Arcutis Biotherapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcutis Biotherapeutics are expected to grow in the coming year, from ($1.60) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcutis Biotherapeutics is -3.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcutis Biotherapeutics is -3.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcutis Biotherapeutics has a P/B Ratio of 10.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arcutis Biotherapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In fact, according to Tucker Carlson, in private even "Obama is telling people Biden can't win, and he is therefore in favor of an open convention."WHO will they replace Biden with? About Arcutis Biotherapeutics Stock (NASDAQ:ARQT)Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Read More ARQT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARQT Stock News HeadlinesJuly 3 at 5:47 AM | insidertrades.comInsider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Sells 10,000 Shares of StockJuly 4 at 1:58 AM | americanbankingnews.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Short Interest UpdateJuly 5, 2024 | Behind the Markets (Ad)Massive July 4th Discount InsideTo celebrate this Independence Day, we've arranged a special deal for you... We've partnered with Behind the Markets to make sure YOU get access to an exclusive 90% off sale not being offered to the public.July 3 at 4:00 PM | globenewswire.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 3 at 5:50 AM | americanbankingnews.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Howard G. Welgus Sells 10,000 Shares of StockJune 27, 2024 | americanbankingnews.comContrasting Arcutis Biotherapeutics (NASDAQ:ARQT) & CannaPharmaRX (OTCMKTS:CPMD)June 13, 2024 | investorplace.comHave $5-10? 7 Affordable Stocks That Are About to Breakout.June 10, 2024 | globenewswire.comArcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema ConferenceJuly 5, 2024 | Behind the Markets (Ad)Massive July 4th Discount InsideTo celebrate this Independence Day, we've arranged a special deal for you... We've partnered with Behind the Markets to make sure YOU get access to an exclusive 90% off sale not being offered to the public.June 5, 2024 | globenewswire.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 24, 2024 | finance.yahoo.comAnalysts Are Betting On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) With A Big Upgrade This WeekMay 20, 2024 | seekingalpha.comArcutis Stock: Sales Expansion Momentum Puts It On A Good TrajectoryMay 15, 2024 | markets.businessinsider.comUpgraded Buy Rating and Price Target for Arcutis Biotherapeutics Amid Zoryve’s Robust Sales PerformanceMay 15, 2024 | msn.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2024 Earnings Call TranscriptMay 15, 2024 | finance.yahoo.comQ1 2024 Arcutis Biotherapeutics Inc Earnings CallMay 15, 2024 | markets.businessinsider.comA Balanced Outlook: Maintaining Hold on Arcutis Amidst Zoryve’s Mixed Performance and Potential Growth CatalystsMay 15, 2024 | finance.yahoo.comArcutis Biotherapeutics Inc (ARQT) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...May 14, 2024 | msn.comArcutis Biotherapeutics Stock Climbs After Blockbuster Q1 ResultsMay 14, 2024 | investorplace.comARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q1 2024May 14, 2024 | markets.businessinsider.comArcutis Biotherapeutics: Strong Prescription Growth Fuels Buy RatingMay 14, 2024 | globenewswire.comArcutis Announces First Quarter 2024 Financial Results and Provides Business UpdateMay 13, 2024 | msn.comArcutis Biotherapeutics Q1 2024 Earnings PreviewMay 13, 2024 | globenewswire.comExpert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic DermatologyMay 4, 2024 | finanznachrichten.deArcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 3, 2024 | globenewswire.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 29, 2024 | globenewswire.comArcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024April 26, 2024 | finance.yahoo.comIndustry Analysts Just Made A Captivating Upgrade To Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue ForecastsSee More Headlines Receive ARQT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/04/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ARQT CUSIPN/A CIK1787306 Webwww.arcutis.com Phone805-418-5006FaxN/AEmployees296Year Founded2016Price Target and Rating Average Stock Price Target$25.38 High Stock Price Target$50.00 Low Stock Price Target$8.00 Potential Upside/Downside+164.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-262,140,000.00 Net Margins-204.35% Pretax Margin-201.12% Return on Equity-197.28% Return on Assets-60.67% Debt Debt-to-Equity Ratio0.90 Current Ratio9.89 Quick Ratio9.61 Sales & Book Value Annual Sales$59.61 million Price / Sales18.64 Cash FlowN/A Price / Cash FlowN/A Book Value$0.94 per share Price / Book10.21Miscellaneous Outstanding Shares115,760,000Free Float104,766,000Market Cap$1.11 billion OptionableOptionable Beta1.18 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Todd Franklin Watanabe M.A. (Age 56)President, CEO & Director Comp: $1.01MDr. Bhaskar Chaudhuri Ph.D. (Age 69)Co-Founder & Independent Director Comp: $60.83kDr. Patrick E. Burnett M.D. (Age 52)Ph.D., Senior VP & Chief Medical Officer Comp: $722.94kMr. L. Todd Edwards (Age 60)Senior VP & Chief Commercial Officer Comp: $755.64kMr. David J. Topper (Age 66)Senior VP & Chief Financial Officer Mr. Rajvir MadanChief Digital & Technology OfficerMs. Latha VairavanVice President of Finance & Investor RelationsMs. Courtney Barton (Age 41)VP and Chief Compliance Officer & Privacy Officer Mr. Masaru Matsuda Esq. (Age 53)J.D., Senior VP, General Counsel & Corporate Secretary Comp: $626.22kMs. Amanda SheldonHead of Corporate CommunicationsMore ExecutivesKey CompetitorsOcular TherapeutixNASDAQ:OCULInnovivaNASDAQ:INVAKiniksa PharmaceuticalsNASDAQ:KNSASupernus PharmaceuticalsNASDAQ:SUPNPhathom PharmaceuticalsNASDAQ:PHATView All CompetitorsInsiders & InstitutionsHoward G WelgusSold 10,000 sharesTotal: $93,100.00 ($9.31/share)Patrick BurnettSold 23,000 sharesTotal: $201,250.00 ($8.75/share)Masaru MatsudaSold 1,775 sharesTotal: $15,992.75 ($9.01/share)Farallon Capital Management LLCBought 1,780,000 shares on 5/24/2024Ownership: 1.538%Ikarian Capital LLCBought 589,642 shares on 5/17/2024Ownership: 0.510%View All Insider TransactionsView All Institutional Transactions ARQT Stock Analysis - Frequently Asked Questions Should I buy or sell Arcutis Biotherapeutics stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcutis Biotherapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ARQT shares. View ARQT analyst ratings or view top-rated stocks. What is Arcutis Biotherapeutics' stock price target for 2024? 8 Wall Street analysts have issued 1 year target prices for Arcutis Biotherapeutics' stock. Their ARQT share price targets range from $8.00 to $50.00. On average, they anticipate the company's share price to reach $25.38 in the next twelve months. This suggests a possible upside of 164.3% from the stock's current price. View analysts price targets for ARQT or view top-rated stocks among Wall Street analysts. How have ARQT shares performed in 2024? Arcutis Biotherapeutics' stock was trading at $3.23 at the beginning of 2024. Since then, ARQT stock has increased by 197.2% and is now trading at $9.60. View the best growth stocks for 2024 here. Are investors shorting Arcutis Biotherapeutics? Arcutis Biotherapeutics saw a increase in short interest in June. As of June 15th, there was short interest totaling 26,020,000 shares, an increase of 5.6% from the May 31st total of 24,640,000 shares. Based on an average daily volume of 2,980,000 shares, the days-to-cover ratio is currently 8.7 days. View Arcutis Biotherapeutics' Short Interest. When is Arcutis Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our ARQT earnings forecast. How were Arcutis Biotherapeutics' earnings last quarter? Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) posted its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.28. The company earned $49.57 million during the quarter. Arcutis Biotherapeutics had a negative net margin of 204.35% and a negative trailing twelve-month return on equity of 197.28%. During the same period in the prior year, the company posted ($1.31) EPS. What other stocks do shareholders of Arcutis Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX), BioNTech (BNTX), ServiceNow (NOW), Qualys (QLYS) and AbbVie (ABBV). When did Arcutis Biotherapeutics IPO? Arcutis Biotherapeutics (ARQT) raised $125 million in an initial public offering on Friday, January 31st 2020. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities acted as the underwriters for the IPO and Cantor was co-manager. How do I buy shares of Arcutis Biotherapeutics? Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARQT) was last updated on 7/5/2024 by MarketBeat.com Staff From Our PartnersUrgent Alert: Is the U.S. Implementing a Digital Dollar?Our exclusive guide, "Exploring the Future of the U.S. Dollar in a Digital World," is your essential resource ...Gold Gate Capital | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredUrgent: Safeguard Your Finances from Biden NOWHave you heard about Executive Order 14067? This lesser-known order introduced the Digital Dollar, an alarming...Golden Crest | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.